Yuri E Nikiforov
Overview
Explore the profile of Yuri E Nikiforov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
15592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt G, Fornal I, Doerfler W, Wald A, Keating S, Nikiforova M, et al.
Endocr Relat Cancer
. 2025 Jan;
32(4).
PMID: 39878559
Approximately 10-20% of thyroid cancers are driven by gene fusions, which activate oncogenic signaling through aberrant overexpression, ligand-independent dimerization or loss of inhibitory motifs. We identified 13 thyroid tumors with...
2.
Schumm M, Nikiforov Y, Nikiforova M, Wald A, Tseng C, Smooke-Praw S, et al.
J Clin Endocrinol Metab
. 2024 Nov;
PMID: 39541427
Context: BRAF V600E mutation is the most common genetic driver of papillary thyroid cancer (PTC), where it is found with various allele frequency (AF), reflecting the proportion of cells carrying...
3.
Doerfler W, Nikitski A, Keating S, Spagnolo D, Kaya C, Morariu E, et al.
Endocr Relat Cancer
. 2024 Oct;
31(12).
PMID: 39404355
BRAFK601E is an uncommon mutation typically found in encapsulated follicular-patterned thyroid tumors. Previous studies on BRAFK601E-positive thyroid tumors were conducted before the implementation of the non-invasive follicular neoplasm with papillary-like...
4.
Kurtom S, Liu J, Doerfler W, Calcaterra M, McCoy K, Sada A, et al.
Surgery
. 2024 Oct;
177:108838.
PMID: 39384477
Background: The threshold at which active surveillance can be considered is variable, with some algorithms proposing nonoperative treatment for differentiated thyroid carcinomas ≤2 cm and lobectomy alone for lesions 2.1-4 ...
5.
Starr D, Tjendra Y, Velez Torres J, Gomez-Fernandez C, Khader S, Karslioglu-French E, et al.
Cancer Cytopathol
. 2024 Sep;
133(1):e22904.
PMID: 39258823
Introduction: Thyroid cytopathology cases with suspicious for malignancy (SFM) diagnosis often result in resection. However, molecular testing offers details that may provide additional insights. In this study, the molecular profiles...
6.
French J, Haugen B, Worden F, Bowles D, Gianoukakis A, Konda B, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3757-3767.
PMID: 38922338
Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the...
7.
Williams M, Liu Z, Rossi E, Agarwal S, Ryska A, Al Ghuzlan A, et al.
J Clin Endocrinol Metab
. 2024 Jun;
110(1):166-175.
PMID: 38874075
Context: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced as a new entity replacing the diagnosis of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC). Significant...
8.
Zeng P, Prokopec S, Lai S, Pinto N, Chan-Seng-Yue M, Clifton-Bligh R, et al.
Cell Rep
. 2024 Feb;
43(3):113826.
PMID: 38412093
Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA...
9.
Yang S, Nga M, Bundele M, Chiosea S, Tan S, Lum J, et al.
Cancer Cytopathol
. 2024 Feb;
132(5):309-319.
PMID: 38319805
Background: Most thyroid nodules are benign. It is important to determine the likelihood of malignancy in such nodules to avoid unnecessary surgery. The primary objective of this study was to...
10.
Ohori N, Cuda J, Bastacky S, Yip L, Karslioglu-French E, Morariu E, et al.
Cancer Cytopathol
. 2023 Oct;
132(2):109-118.
PMID: 37849056
Background: Indeterminate thyroid cytopathology diagnoses represent differing degrees of risk that are corroborated by follow-up studies. However, traditional cytologic-histologic correlation may overestimate the risk of malignancy (ROM) because only a...